Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Company Data

Name Petros Pharmaceuticals, Inc. - Common Stock

Company Petros Pharmaceuticals, Inc.

Symbol PTPI

Website https://www.petrospharma.com

Primary Exchange

NASDAQ

ISIN US71678J2096

Asset Class Share

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

CEO Fady Boctor

Country United States of America

Currency USD

Employees 0,0 T

Address 1185 Avenue of the Americas, 10036 New York City

IPO Date 2020-12-02

Stock Splits

Date	Split
01.05.2025	1:25

Ticker Symbols

Name	Symbol
NASDAQ	PTPI

More Shares

Investors who hold Petros Pharmaceuticals, Inc. - Common Stock also have the following shares in their portfolio:

HITACHI CAPITAL (UK) PLC 0.95% NTS 08/02/24 Bond

TELSTRA GROU 23/31 MTN Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog